Platelet activation relieves liver portal hypertension via the lymphatic system though the classical vascular endothelial growth factor receptor 3 signaling pathway

Figure 7 Inhibition of vascular endothelial growth factor C/vascular endothelial growth factor receptor 3 reverses the amelioration of intrahepatic angiogenesis and inflammation by platelet-rich plasma-induced platelets. A: Representative immunohistochemistry images of von Willebrand factor (vWF), matrix metalloproteinase 2 (MMP2), vascular endothelial growth factor A (VEGF-A), cluster of differentiation 31 (CD31) and CD68 in the livers of different groups; Quantitative analysis of B: vWF; C: MMP2; D: VEGF-A; E: CD31; F: CD68. The data represent the mean ± SD. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. BDL: Bile duct ligation; PRP: Platelet-rich plasma; VEH: Vehicle.